The Role of FGF23 and Asymmetric Dimethylarginine (ADMA) in Chronic Kidney Disease

Ankara Education and Research Hospital

Status: Unknown

Conditions: Chronic Kidney Disease; Metabolic Diseases

Study type: Observational

Funder types: Other

Identifiers

NCT01317186

NEPH002

Details and patient eligibility

About

In chronic kidney disease calcium (Ca) and phosphate (P) metabolism disorders are very common and also they are one of the leading causes of morbidity in these population. FGF23 is a novel factor that contributes Ca-P disorders. It has been hypothesized that FGF 23 increase is mediated by asymmetric dimethylarginine (ADMA). The aim of the study is to evaluate this hypothesis.

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• between ages of 18 - 65 years old
• chronic kidney disease of stage 2-4

Exclusion criteria

• presence of diabetes mellitus or ischemic hearth disease
• taking vitamin d therapy

Trial design

100 participants in 3 patient groups

Group I

Description:

Stage 2 Non-diabetic Chronic Kidney Disease

Group II

Description:

Stage 3 Non-diabetic Chronic Kidney Disease

Group III

Description:

Stage 4 Non-diabetic Chronic Kidney Disease